1) Patients with BMI >27 kg/m(2) were rand |
2) Patients with HHcy (group A) received basi |
3) Patients with acute ischemic stroke with p |
4) Patients with antiheparin/PF4 IgG had a hi |
5) Patients with antiheparin/PF4 IgG were old |
6) Patients with clinically negative nodes ma |
7) Patients with diverse type of wounds were |
8) Patients with none (n = 10 508), 1 (n = 88 |
9) Patients with severe acute and chronic low |
10) 95 patients with 107 overdentures were suppor |
11) The stability of patients with 80 implants was monitored wi |
12) Approximately, one-third of patients with ABC present simultaneously w |
13) morphism of IL-1α gene were genotyped in patients with AD and controls. |
14) ificantly increased Gal-3 serum levels in patients with AD compared to control parti |
15) of 24-healthy elderly participants and 26 patients with AD without delusional syndro |
16) ed the characteristics and outcomes of 49 patients with AHA diagnosed in our center |
17) ive and safe to control acute bleeding in patients with AHA. |
18) We performed surgery on 4 patients with CNFT and report here good re |
19) A total of 300 patients with COPD aged 50 to 75 years wer |
20) ent neural models of face perception, our patients with Capgras syndrome may be rela |
21) IgG in old age or low antithrombin level patients with DIC with old age or low anti |
22) automated chemiluminescence system in 118 patients with DIC. |
23) ing HeartShield is beneficial in treating patients with DSWI. |
24) use of neoadjuvant chemo(radio)therapy of patients with EAC. |
25) arize and to present proper management of patients with IBD prior to conception, as |
26) The great majority of patients with IH will not need treatment, |
27) revalence and clinical characteristics of patients with LGV since 2007 when active c |
28) Medical records of all patients with LGV were reviewed. |
29) We classified 355 patients with NSTE-ACS according to the ad |
30) s not associated with adverse outcomes in patients with NSTE-ACS treated with dual a |
31) exist to ameliorate clinical symptoms in patients with PAD. |
32) The median survival time of patients with PUs was significantly lower |
33) festyle, disease and therapy variables in patients with RA. |
|